-
Despite previous positive reports and much lay enthusiasm, omega-3 fatty acid treatment did not prevent Crohn's disease relapse. (Arguments continue as to whether the correct usage should be "Crohn disease" or "Crohn's disease." Most of the literature seems to use the latter designation, and this review will do likewise.)
-
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Because the consequence of missed pulmonary embolism (PEM) is so grave, it is essential to continue our evolution of tools which maximize diagnostic sensitivity, offer clinical expedience, and minimize risk for the patient.
-
Regadenoson, the first selective A2A adenosine receptor agonist, has been approved for use as a pharmacologic stress agent for nuclear medicine stress testing (radionuclide myocardial perfusion imaging).
-
-
Exactly 1397 antiretroviral (ARV) naïve patients initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years.
-
-
In the health care setting, transmission of varicella zoster virus (VZV) from dermatomal herpes zoster lesions is generally felt to be insignificant, as long as the lesions are kept covered.
-
Pneumococcal meningitis remains a deadly disease, with a case fatality rate among adults that is still above 20%, with also permanent neurological sequelae in a substantial minority of survivors.